--Advertisement--

NCDC reports one monkeypox death as cases rise to 157

Monkeypox Monkeypox
Mpox. Photo credit: NCDC

The Nigeria Centre for Disease Control (NCDC) says it recorded one new monkeypox death, bringing the total number of monkeypox deaths in 2022 to four.

The agency, in its latest monkeypox situation report, said from July 25 to July 31, there were 24 new confirmed positive cases from 12 states – Ondo (5), Kano (3), Lagos (3), Abia (2), Adamawa (2), Bayelsa (2), Kwara (2), Delta (1), Anambra (1), Gombe (1), Rivers (1) and Nasarawa (1).

“From 1st January to 31st July 2022, there have now been 413 suspected cases and 157 confirmed cases (105 male, 52 female) from twenty-six (26) states – Lagos (20), Ondo (14), Adamawa (13), Delta (12), Bayelsa (12), Rivers (11), Edo (8), Nasarawa (8), Plateau (6), Anambra (6), FCT (5), Taraba (5), Kwara (5), Kano (5), Imo (4), Cross River (3), Borno (3), Oyo (3), Abia (3), Gombe (3), Katsina (2), Kogi (2), Niger (1), Ogun (1), Bauchi (1) and Akwa Ibom (1),” the report reads.

“Four deaths were recorded from 4 states – Delta (1), Lagos (1), Ondo (1) and Akwa Ibom (1).

Advertisement

“Overall, since the re-emergence of monkeypox in September 2017 and to 31st July 2022, a total of 925 suspected cases have been reported from 35 states in the country.

“Of these 925 suspected cases, there have been 383 (41.5%) confirmed (253 male, 130 female) from 30 states – Rivers (63), Bayelsa (55), Lagos (50), Delta (41), Edo (18), Cross River (17), Ondo (14), Adamawa (13), Imo (12), FCT (11), Nasarawa (10), Oyo (9), Plateau (9), Akwa Ibom (8), Anambra (8). Abia (6), Kano (5), Taraba (5), Kwara (5), Enugu (4), Borno (3), Gombe (3), Benue (2), Ekiti (2), Niger (2), Ogun (2), Katsina (2), Kogi (2), Ebonyi (1), and Bauchi (1).

“In addition, from September 2017 to July 31, 2022, a total of twelve (12) deaths have been recorded (CFR= 3,1%) in nine states Lagos (3), Edo (2), Imo (1), Cross River (1), FCT (1), Rivers (1), Ondo (1) Delta (1) and Akwa Ibom (1).”

Advertisement
Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected from copying.